215 related articles for article (PubMed ID: 29123930)
41. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
[TBL] [Abstract][Full Text] [Related]
42. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
Roti G; La Starza R; Gorello P; Gottardi E; Crescenzi B; Martelli MF; Mecucci C
Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
[TBL] [Abstract][Full Text] [Related]
43. Bilineal Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia: A Case Report and Literature Review.
Gao X; Li J; Wang L; Lin J; Jin H; Xu Y; Wang N; Zhao Y; Liu D; Yu L; Wang Q
Am J Case Rep; 2016 Oct; 17():793-798. PubMed ID: 27784881
[TBL] [Abstract][Full Text] [Related]
44. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
45. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
46. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
[TBL] [Abstract][Full Text] [Related]
47. A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation.
Imataki O; Ishida T; Kubo H; Uemura M; Nanya Y; Kawakami K; Ogawa S; Kadowaki N
Case Rep Oncol; 2020; 13(1):449-455. PubMed ID: 32399015
[TBL] [Abstract][Full Text] [Related]
48. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3
Massimino M; Stella S; Tirrò E; Consoli ML; Pennisi MS; Puma A; Vitale SR; Romano C; Zammit V; Stagno F; DI Raimondo F; Manzella L
Anticancer Res; 2019 Jul; 39(7):3949-3954. PubMed ID: 31262926
[TBL] [Abstract][Full Text] [Related]
50. Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm.
Frederick L; Beardell F; Viswanatha DS
Hum Pathol; 2014 Aug; 45(8):1784-9. PubMed ID: 24927924
[TBL] [Abstract][Full Text] [Related]
51. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
[TBL] [Abstract][Full Text] [Related]
52. Development and validation of sensitive BCR::ABL1 fusion gene quantitation using next-generation sequencing.
Lee H; Seo J; Shin S; Lee ST; Choi JR
Cancer Cell Int; 2023 May; 23(1):106. PubMed ID: 37248544
[TBL] [Abstract][Full Text] [Related]
53. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
Vasconcelos AP; Azevedo IF; Melo FCBC; Neves WB; Azevedo ACAC; Melo RAM
Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28437552
[TBL] [Abstract][Full Text] [Related]
54. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Significance of Transcript-Type
Molica M; Abruzzese E; Breccia M
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020062. PubMed ID: 32952973
[TBL] [Abstract][Full Text] [Related]
56. CML with e6a2 BCR-ABL1 transcript: an aggressive entity?
Beel KA; Lemmens J; Vranckx H; Maertens J; Vandenberghe P
Ann Hematol; 2011 Oct; 90(10):1241-3. PubMed ID: 21302112
[No Abstract] [Full Text] [Related]
57. Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients.
Cumbo C; Impera L; Minervini CF; Orsini P; Anelli L; Zagaria A; Coccaro N; Tota G; Minervini A; Casieri P; Brunetti C; Rossi AR; Parciante E; Specchia G; Albano F
Oncotarget; 2018 Feb; 9(13):10978-10986. PubMed ID: 29541390
[TBL] [Abstract][Full Text] [Related]
58. Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances.
Cumbo C; Anelli L; Specchia G; Albano F
Cancer Manag Res; 2020; 12():3175-3189. PubMed ID: 32440215
[TBL] [Abstract][Full Text] [Related]
59. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
Salem A; Loghavi S; Tang G; Huh YO; Jabbour EJ; Kantarjian H; Wang W; Hu S; Luthra R; Medeiros LJ; Khoury JD
Am J Hematol; 2017 Jun; 92(6):520-528. PubMed ID: 28253536
[TBL] [Abstract][Full Text] [Related]
60. Atypical activation of signaling downstream of inactivated Bcr-Abl mediates chemoresistance in chronic myeloid leukemia.
Narasimhan M; Khamkar V; Tilwani S; Dalal SN; Shetty D; Subramanian PG; Gupta S; Govekar R
J Cell Commun Signal; 2022 Jun; 16(2):207-222. PubMed ID: 34596797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
